Literature DB >> 11068171

Cyclosporine A neurotoxicity in a patient with idiopathic renal magnesium wasting.

A K Al-Rasheed1, S I Blaser, B A Minassian, L Benson, S K Weiss.   

Abstract

We report a female child who had idiopathic renal magnesium wasting secondary to suspected Gitleman syndrome and cyclosporine A neurotoxicity after a heart transplant. The child had acute, progressive encephalopathy, intractable seizures, quadriparesis, and extensive, bilateral cortical involvement on neuroimaging. Two days after discontinuation of the cyclosporine, the child's condition improved dramatically, including an improved level of consciousness, and she became seizure free. By 6 weeks, she was fully ambulatory. Follow-up magnetic resonance imaging and electroencephalograms demonstrated significant improvement. This patient had drug-induced neurotoxicity, exacerbated by hypomagnesemia. Cyclosporine should be used cautiously in transplant patients with Gitelman syndrome or other acquired magnesium homeostasis disorders because of the possible increased risk of neurotoxicity. This report is the first case of a patient with both cyclosporine neurotoxicity and magnesium-wasting nephropathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068171     DOI: 10.1016/s0887-8994(00)00198-3

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

Review 1.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Posterior Reversible Encephalopathy Syndrome in a Bone Marrow Transplant Patient: A Complication of Immunosuppressive Drugs?

Authors:  Mohammad A Hossain; Waqas Jehangir; Qiang Nai; Naureen Jessani; Rafay Khan; Abdalla Yousif; Shuvendu Sen
Journal:  World J Oncol       Date:  2015-08-27

Review 3.  An overview of diagnosis and management of drug-induced hypomagnesemia.

Authors:  George Liamis; Ewout J Hoorn; Matilda Florentin; Haralampos Milionis
Journal:  Pharmacol Res Perspect       Date:  2021-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.